Introduction
============

Atherosclerotic lesion of the aortic arch is a common etiology for ischemic stroke^[@bib1],\ [@bib2])^. Aortic arch calcification (AAC), a surrogate measure for atherosclerosis, can be readily detected with chest radiography^[@bib3],\ [@bib4])^. AAC was proposed as a satisfactory index for measuring systemic atherosclerosis burden^[@bib5],\ [@bib6])^ and was associated with cardiovascular events^[@bib2],\ [@bib7],\ [@bib8])^.

Growing evidence indicated that genetic factors may affect the initiation and development of artery calcification^[@bib9],\ [@bib10])^. The human chromosome 9p21 (Chr9p21), for example, has been associated with both atherosclerosis and arterial calcification in several genome-wide association studies^[@bib11]--[@bib13])^. As a chromosome region devoid of protein-coding genes, Chr9p21 only transcribes a long non-coding RNA, namely antisense noncoding RNA in the INK4 locus (*ANRIL*). The closest protein-coding genes to Chr9p21 locus are two cyclin-dependent kinase inhibitors, *CDKN2A* and *CDKN2B*, both of which are involved in cell cycle regulation. Previous studies showed that variations in Chr9p21 may increase the levels of *ANRIL* transcription, which in turn downregulate *CDKN2A/2B* expression and enhance cell proliferation, and subsequently promote atherosclerosis^[@bib14],\ [@bib15])^. Studies also confirmed that *ANRIL* could bind and recruit epigenetic modifiers to *CDKN2A/2B* and induce DNA methylation^[@bib16],\ [@bib17])^.

Aim
===

Considering *CDKN2A/2B* involved in the development of atherosclerotic diseases^[@bib18],\ [@bib19])^, and DNA methylation of *CDKN2A/2B* has been frequently reported in many conditions^[@bib20],\ [@bib21])^, we hypothesized that *CDKN2A/2B* methylation may increase the susceptibility of AAC. We tested this hypothesis in a group of Chinese patients with ischemic stroke who were at a high risk of developing atherosclerosis and calcification.

Methods
=======

Study Population
----------------

This study was approved by the Ethical Review Board of Jinling Hospital. Informed consent was obtained from all enrolled patients. Consecutive patients with ischemic stroke aged ≥ 18 years were screened from Nanjing Stroke Registry Program (NSRP)^[@bib22])^ between July 2012 and September 2013. Patients with malignant neoplasm, severe liver or kidney diseases, autoimmune diseases, parathyroid gland diseases, or calcium--phosphorus metabolism disorders were excluded. As stents may influence the accuracy of calcification assessment, patients with a history of stenting treatment in aortic arch, brachiocephalic trunk, subclavian arteries, and common carotid arteries were also excluded. Finally, 324 patients were enrolled. Demographic characteristics and cardiovascular risk factors, which included age, sex, history of hypertension (HTN) and diabetes mellitus (DM), dyslipidemia, cigarette smoking, and alcohol drinking, were collected.

Artery Calcification Measurement
--------------------------------

Each enrolled patient underwent neck computed tomography angiography (CTA) for AAC evaluation. CTA was performed with a dual-source 64 slice CT system (Siemens, Forchheim, Germany). Imaging was acquired by scanning from 4 cm below the aortic arch to the superior border of the orbit in craniocaudal direction. The aortic arch was recognized as a section from the initial segment to the first centimeter of the common carotid, vertebral, and subclavian arteries beyond the origin of the vertebral arteries. Details of scanning parameters have been reported elsewhere^[@bib23])^. Calcification scores in the aortic arch were measured with the Syngo Calcium Scoring system (Siemens, Forchheim, Germany). A focus of ≥ 4 contiguous pixels accompanied with a CT density of ≥ 130 Hounsfield units (HU) was defined as calcification according to the method of Agatston score^[@bib24])^. For each calcified lesion, the Agatston score was calculated as the product of the area (mm^2^) and a factor assigned according to the maximum attenuation value of the lesion (HU = 130--199 \[1\], 200--299 \[2\], 300--399 \[3\], \> 399 \[4\]). The total score of the aortic arch was calculated by adding up the scores of all lesions. Finally, patients with Agatston score of 0 or \> 0 were dichotomized into groups without or with AAC, respectively. Calcification scores were dual-assessed by two radiologists who were blinded to epi-genotyping results.

DNA Isolation and Genotyping
----------------------------

Venous blood samples were drawn in the morning after an overnight fasting for assaying biochemical parameters and epi-genotyping. Genomic DNA was extracted from whole blood using commercially available kits (TIANGEN Biotech, Beijing, China). DNA was quantified and then diluted to a working concentration of 10 ng/uL. Rs4977574 at Chr9p21, which is significantly associated with calcification in the aorta based on the validation of a previous study^[@bib25])^, was selected for genotyping. Single nucleotide polymorphism of rs4977574 (AA, AG, GG) was genotyped via polymerase chain reaction ligase detection reaction with an ABI Prism 377 Sequence Detection System (Applied Biosystems, CA, USA)^[@bib26])^. Sequencing primers were CATGCTTTCTGAAACAACACG (forward) and TAATGGAGGTGTGGTCAGCA (reverse). Reproducibility of genotyping was confirmed by randomly selecting 10% of the samples, and the concordance was 100%.

DNA Methylation Analysis
------------------------

CpG islands adjacent to promoter regions of *CDKN2A/2B* were selected for measurement according to the following criteria: (1) 200 bp minimum length; (2) ≥ 50% GC content; (3) ≥ 0.60 ratio of observed/expected dinucleotides CpG^[@bib27])^. Six CpG regions from CpG islands of *CDKN2A* and three from those of *CDKN2B* were sequenced. Bisulfite conversion of 1 ug genomic DNA was performed using the EZ DNA Methylation™-GOLD Kit (ZYMO RESEARCH, CA, USA) according to the manufacturer\'s protocol. Sodium bisulfite can preferentially deaminate un-methylated cytosine residues to thymines, whereas methyl-cytosines remain unmodified. After PCR amplification (HotStarTaq polymerase kit, TAKARA, Tokyo, Japan) of target CpG regions and library construction, products were sequenced using Illumina MiSeq Benchtop Sequencer (CA, USA) in accordance with the method of BiSulfite Amplicon Sequencing^[@bib28])^. Primer sequences used for PCR were shown in **[Supplemental Table 1](#S1){ref-type="table"}**. All samples achieved a mean coverage of \> 600 X. Methylation levels of 24 CpG sites in *CDKN2A* and 12 sites in *CDKN2B* were measured. Each tested CpG site was named as its relative distance (in bp) to transcriptional start site and listed in **[Supplemental Table 2](#S2){ref-type="table"}**. The methylation level of each CpG site was calculated as the percentage of the methylated cytosines over total tested cytosines. The average methylation level was calculated using methylation levels of all measured CpG sites within the gene.

###### Primer sequences for *CDKN2A/2B* genes (start and end site were named as its relative distance to transcriptional start site)

  Gene       PCR size (bp)   Start site   End site   Primer    
  ---------- --------------- ------------ ---------- --------- -----------------------------------
  *CDKN2A*   282             −1477        −1197      forward   GGGATATGGAGGGGGAGAT
                                                     reverse   CTTCTTCCTCTTTCCTCTTCCC
             211             −1047        −838       forward   GGGAAGAGGAAAGAGGAAGAAG
                                                     reverse   ATTAAACTAAACCRCTACACRCCTCTAAC
             286             −859         −574       forward   AATAAAATAAGGGGAATAGGGGAG
                                                     reverse   CCATCTTCCCACCCTCAA
             188             −399         −212       forward   GTAGTTAAGGGGGTAGGAGTGG
                                                     reverse   ACTACTACCCTAAACRCTAACTCCTCAA
             266             +70          +335       forward   TTGAGGAGTTAGYGTTTAGGGTAGTAGT
                                                     reverse   TCAATAATACTACRAAAACCACATATCTAAATC
             224             +308         +531       forward   GTYGGTTGGTTTTTTATTTTGTTAGAG
                                                     reverse   AACCTAAACTCAACTTCATTACCCTC
                                                               
  *CDKN2B*   255                 −7       +248       forward   GAGGGTAATGAAGTTGAGTTTAGGTT
                                                     reverse   CTATCRCACCTTCTCCACTAATCC
             234             +223         +455       forward   GGGGATTAGTGGAGAAGGTG
                                                     reverse   TAAAATACACACCTCCRACCAAC
             221             +430         +650       forward   TGTTTTTTAAGTTTTTATAGGGTGAGG
                                                     reverse   CCAACCTAACCAAAATAATAAAAACC

###### Methylated CpG sites measured in this study.

  Gene       Position   Genomic location[\*](#tf1){ref-type="table-fn"}   Relative to TSS, bp
  ---------- ---------- ------------------------------------------------- ---------------------
  *CDKN2A*   1          Chr9: 21995909                                    −1419
             2          Chr9: 21995896                                    −1406
             3          Chr9: 21995867                                    −1377
             4          Chr9: 21995713                                    −1223
             5          Chr9: 21995470                                    −980
             6          Chr9: 21995457                                    −967
             7          Chr9: 21995455                                    −965
             8          Chr9: 21995354                                    −864
             9          Chr9: 21995314                                    −824
             10         Chr9: 21995312                                    −822
             11         Chr9: 21995305                                    −815
             12         Chr9: 21995108                                    −618
             13         Chr9: 21994859                                    −369
             14         Chr9: 21994782                                    −292
             15         Chr9: 21994734                                    −244
             16         Chr9: 21994727                                    −237
             17         Chr9: 21994286                                    +205
             18         Chr9: 21994215                                    +276
             19         Chr9: 21994211                                    +280
             20         Chr9: 21994208                                    +283
             21         Chr9: 21994155                                    +336
             22         Chr9: 21994109                                    +382
             23         Chr9: 21994076                                    +415
             24         Chr9: 21993993                                    +498
                                                                          
  *CDKN2B*   1          Chr9: 22009259                                    +54
             2          Chr9: 22009179                                    +134
             3          Chr9: 22009165                                    +148
             4          Chr9: 22009134                                    +179
             5          Chr9: 22009000                                    +313
             6          Chr9: 22008981                                    +332
             7          Chr9: 22008956                                    +357
             8          Chr9: 22008890                                    +423
             9          Chr9: 22008845                                    +468
             10         Chr9: 22008830                                    +483
             11         Chr9: 22008815                                    +498
             12         Chr9: 22008804                                    +509

The chromosomal location of each CpG site according to assembly GRCh37/hg19.

Statistical Analysis
--------------------

Normality of quantitative variables was assessed using Shapiro--Wilk test. As all continuous data in this study did not meet the normality assumption, they were described as median (interquartile range) and compared using Mann--Whitney *U* test. Categorical variables were compared using Fisher\'s exact test.

Spearman correlations were used to evaluate pair-wise correlations of methylation levels between different CpG sites in the same gene. Considering the extremely left-skewed distribution of calcification scores, we added 1 to each calcification score, and the value was then log-transformed as the formula: Ln (calcification score + 1). This transformation may result in a less skewed distribution, as suggested in previous studies^[@bib13],\ [@bib25])^. Generalized linear model was used to explore the association between methylation levels and log-transformed calcification scores, adjusting for potential confounders including age, sex, HTN, DM, dyslipidemia, and smoking. For multiple testing, Bonferroni correction was performed. Kruskal--Wallis test was performed to compare methylation levels across the genotypes of rs4977574 (AA, AG, and GG).

Data were analyzed using IBM SPSS Statistics Version 22.0 (Armonk, NY: IBM Corp.). A two-tailed value of *P* \< 0.05 was considered statistically significant.

Results
=======

Of the 324 enrolled participants, 2 (0.6%) failed in epi-genotyping. Finally, 322 (99.4%) patients were included for data analysis. Baseline characteristics were listed in **[Table 1](#T1){ref-type="table"}**. The median age of these 322 patients was 62.0 (55.0--70.0) years, and 229 (71.1%) of them were males. Of these analyzed patients, 250 (77.6%) had a history of HTN and 110 (34.2%) had a history of DM.

###### Baseline characteristics of the study participants.

  Variants              All (*n* = 322)
  --------------------- --------------------
  Age, years            62.0 (55.0--70.0)
  Male, n (%)           229 (71.1)
  HTN, n (%)            250 (77.6)
  DM, n (%)             110 (34.2)
  Dyslipidemia, n (%)   176 (54.7)
  TC, mmol/L            4.21 (3.58--5.00)
  TG, mmol/L            1.40 (1.09--1.88)
  HDL-c, mmol/L         0.98 (0.82--1.15)
  LDL-c, mmol/L         2.61 (1.93--3.18)
  Glucose, mmol/L       5.3 (4.6--6.6)
  Smoking, n (%)        132 (41.0)
  Drinking, n (%)       96 (29.8)
  AAC, n (%)            248 (77.0%)
  AAC score             221.5 (3.8--803.7)
  Ln (AAC+1)            5.40 (1.56--6.69)

Data are presented as number of individuals (%) or median (interquartile range).

AAC, artic arch calcification; HTN, hypertension; DM, diabetes mellitus; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Based on Agatston scores, there were 248 (77.0%) and 74 (23.0%) patients classified as with and without AAC, respectively. AAC scores presented a highly skewed distribution with a median (interquartile range) of 221.5 (3.8--803.7). Compared with patients without AAC, those with AAC were older (64.0 vs 49.0 years, *P* \< 0.001), had a higher prevalence of HTN (83.1% vs 59.5%, *P* \< 0.001), lower prevalence of dyslipidemia (51.6% vs 64.9%, *P* = 0.047), and higher HDL-c levels (1.00 vs 0.91, *P* = 0.048) (**[Table 2](#T2){ref-type="table"}**).

###### Comparison of demographic characteristics of patients with and without AAC.

  Variants              AAC                 *P* value           
  --------------------- ------------------- ------------------- --------------
  Age, years            64.0 (58.0--72.0)   49.0 (43.8--58.3)   **\< 0.001**
  Male, n (%)           171 (69.0)          58 (78.4)           0.144
  HTN, n (%)            206 (83.1)          44 (59.5)           **\< 0.001**
  DM, n (%)             86 (34.7)           24 (32.4)           0.781
  Dyslipidemia, n (%)   128 (51.6)          48 (64.9)           **0.047**
  TC, mmol/L            4.27 (3.55--5.01)   4.16 (3.69--4.78)   0.756
  TG, mmol/L            1.37 (1.06--1.76)   1.58 (1.15--2.03)   0.064
  HDL-c, mmol/L         1.00 (0.83--1.16)   0.91 (0.79--1.06)   **0.048**
  LDL-c, mmol/L         2.63 (1.93--3.20)   2.60 (1.93--3.09)   0.995
  Glucose, mmol/L       5.3 (4.7--6.7)      5.3 (4.6--6.6)      0.670
  Smoking, n (%)        97 (39.1)           35 (47.3)           0.227
  Drinking, n (%)       71 (28.6)           25 (33.8)           0.390

Methylation levels of 36 CpG sites were listed in **[Supplemental Table 3](#S3){ref-type="table"}**. Methylation levels of CpG sites measured within *CDKN2A* were not strongly correlated, whereas those within *CDKN2B* were well correlated (**[Supplemental Table 4](#S4){ref-type="table"}--[5](#S5){ref-type="table"}**). As shown in **[Table 3](#T3){ref-type="table"}**, univariate comparison of these 36 sites and the average methylation levels indicated that methylation levels of *CDKN2B* were higher in patients with AAC than in those without AAC ( 5.72 vs 4.94, *P* \< 0.001).

###### Distribution of methylation levels (%) of 36 CpG sites in *CDKN2A/2B* genes.

  Gene       Position   Min    Q1      Median   Q3      Max
  ---------- ---------- ------ ------- -------- ------- -------
  *CDKN2A*   1          0.00   2.81    4.26     5.94    17.19
             2          0.00   5.31    6.98     8.82    19.69
             3          0.00   6.53    8.08     10.17   21.40
             4          0.00   4.27    5.83     7.85    18.60
             5          0.00   4.08    4.89     5.49    9.66
             6          0.00   2.29    2.71     3.29    9.23
             7          0.00   1.84    2.33     2.79    7.69
             8          1.79   3.69    4.37     5.03    10.44
             9          0.00   2.44    4.42     7.90    23.53
             10         0.00   0.98    1.97     3.14    8.82
             11         0.00   2.38    3.61     4.93    13.33
             12         0.00   0.57    0.93     1.33    2.85
             13         0.00   0.95    1.21     1.50    2.60
             14         0.00   0.97    1.18     1.44    2.94
             15         0.00   1.64    2.05     2.43    6.86
             16         0.00   1.03    1.34     1.65    3.37
             17         0.00   2.59    3.17     3.83    25.26
             18         0.49   1.72    2.18     2.58    7.49
             19         0.00   2.01    2.49     2.95    7.49
             20         0.44   2.17    2.72     3.24    8.85
             21         4.86   13.74   15.51    17.20   34.15
             22         0.71   2.07    2.57     3.18    8.62
             23         0.00   3.50    4.27     5.05    10.98
             24         0.00   1.26    1.70     2.46    6.17
             Average    2.39   3.61    3.94     4.25    6.15
                                                        
  *CDKN2B*   1          1.83   4.42    5.35     6.24    12.21
             2          0.00   3.42    4.37     5.24    10.88
             3          0.00   3.10    3.89     4.82    9.32
             4          0.00   3.34    4.10     4.99    18.82
             5          4.42   6.44    7.40     8.61    16.37
             6          3.44   5.54    6.66     7.78    13.05
             7          4.06   6.84    7.86     9.06    18.45
             8          0.86   2.94    3.41     3.96    12.05
             9          0.00   3.23    3.74     4.36    17.09
             10         0.00   4.95    5.85     6.74    18.04
             11         3.70   6.18    7.13     8.48    27.93
             12         2.43   4.80    5.48     6.45    23.90
             Average    3.45   4.83    5.54     6.15    11.08

Q1: 1st quartile (25th percentile), Q3: 3rd quartile (75th percentile).

###### Spearman pairwise correlations for CpG sites of *CDKN2A*.

  Position   1     2                                    3                                    4                                    5     6                                    7                                    8                                    9      10    11     12                                    13                                   14                                   15                                   16                                    17                                   18                                   19                                   20                                    21                                    22                                   23                                   24
  ---------- ----- ------------------------------------ ------------------------------------ ------------------------------------ ----- ------------------------------------ ------------------------------------ ------------------------------------ ------ ----- ------ ------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------ ------------------------------------- ------------------------------------- ------------------------------------ ------------------------------------ ------------------------------------
  1          1.0   0.5[\*](#tf2){ref-type="table-fn"}   0.4[\*](#tf2){ref-type="table-fn"}   0.4[\*](#tf2){ref-type="table-fn"}   0.0   0.0                                  0.0                                  0.0                                  0.0    0.0   0.0    −0.1[\*](#tf2){ref-type="table-fn"}   0.1                                  −0.1                                 0.0                                  −0.1                                  −0.1                                 −0.1                                 0.0                                  −0.1[\*](#tf2){ref-type="table-fn"}   0.0                                   0.1                                  0.1                                  0.2[\*](#tf2){ref-type="table-fn"}
  2                1.0                                  0.5[\*](#tf2){ref-type="table-fn"}   0.4[\*](#tf2){ref-type="table-fn"}   0.0   0.0                                  0.0                                  0.1[\*](#tf2){ref-type="table-fn"}   0.0    0.0   0.0    0.0                                   −0.1                                 −0.1                                 0.1                                  −0.1[\*](#tf2){ref-type="table-fn"}   0.0                                  0.0                                  0.0                                  0.0                                   0.1                                   0.1                                  0.1[\*](#tf2){ref-type="table-fn"}   0.3[\*](#tf2){ref-type="table-fn"}
  3                                                     1.0                                  0.4[\*](#tf2){ref-type="table-fn"}   0.1   0.0                                  0.0                                  0.1[\*](#tf2){ref-type="table-fn"}   0.0    0.0   0.0    0.0                                   0.0                                  0.0                                  0.1                                  −0.1                                  0.1                                  0.1                                  0.1                                  0.1                                   0.1                                   0.1[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}   0.3[\*](#tf2){ref-type="table-fn"}
  4                                                                                          1.0                                  0.1   0.1                                  0.0                                  0.1                                  0.1    0.0   0.0    −0.1                                  0.1                                  0.0                                  0.1                                  0.0                                   0.1                                  0.0                                  0.0                                  0.0                                   0.0                                   0.1                                  0.1                                  0.2[\*](#tf2){ref-type="table-fn"}
  5                                                                                                                               1.0   0.2[\*](#tf2){ref-type="table-fn"}   0.3[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}   0.0    0.0   0.0    0.1                                   0.2[\*](#tf2){ref-type="table-fn"}   0.1                                  0.1                                  0.2[\*](#tf2){ref-type="table-fn"}    0.0                                  0.1                                  0.1                                  0.0                                   0.0                                   0.0                                  0.0                                  0.1[\*](#tf2){ref-type="table-fn"}
  6                                                                                                                                     1.0                                  0.3[\*](#tf2){ref-type="table-fn"}   0.3[\*](#tf2){ref-type="table-fn"}   −0.1   0.1   0.1    0.1[\*](#tf2){ref-type="table-fn"}    0.1                                  0.2[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}    0.1                                  0.1[\*](#tf2){ref-type="table-fn"}   0.1                                  0.0                                   0.0                                   0.1[\*](#tf2){ref-type="table-fn"}   0.1                                  0.2[\*](#tf2){ref-type="table-fn"}
  7                                                                                                                                                                          1.0                                  0.2[\*](#tf2){ref-type="table-fn"}   0.0    0.1   0.0    0.1                                   0.0                                  0.1                                  0.2[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}    0.0                                  0.1                                  0.1                                  0.0                                   0.0                                   0.0                                  0.0                                  0.1
  8                                                                                                                                                                                                               1.0                                  0.1    0.1   0.1    0.2[\*](#tf2){ref-type="table-fn"}    0.2[\*](#tf2){ref-type="table-fn"}   0.1                                  0.3[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}    0.1[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}   0.1                                  0.1[\*](#tf2){ref-type="table-fn"}    0.0                                   0.1[\*](#tf2){ref-type="table-fn"}   0.1                                  0.1
  9                                                                                                                                                                                                                                                    1.0    0.0   −0.1   0.0                                   0.0                                  0.0                                  0.0                                  0.0                                   0.0                                  −0.1                                 −0.1                                 −0.1[\*](#tf2){ref-type="table-fn"}   −0.1[\*](#tf2){ref-type="table-fn"}   0.0                                  0.0                                  0.0
  10                                                                                                                                                                                                                                                          1.0   0.1    0.0                                   −0.1                                 0.1                                  0.0                                  0.0                                   0.0                                  0.0                                  0.0                                  0.1                                   0.0                                   −0.1                                 0.0                                  0.1
  11                                                                                                                                                                                                                                                                1.0    0.1                                   0.0                                  0.0                                  0.0                                  0.1                                   0.1                                  0.1                                  0.1                                  0.0                                   0.1                                   0.2[\*](#tf2){ref-type="table-fn"}   0.0                                  0.0
  12                                                                                                                                                                                                                                                                       1.0                                   0.0                                  0.0                                  0.1[\*](#tf2){ref-type="table-fn"}   0.1                                   0.1                                  0.1                                  0.1                                  0.1                                   0.0                                   0.1                                  0.0                                  −0.1
  13                                                                                                                                                                                                                                                                                                             1.0                                  0.1                                  0.0                                  0.1[\*](#tf2){ref-type="table-fn"}    0.0                                  0.0                                  0.0                                  0.0                                   0.0                                   0.0                                  0.0                                  0.0
  14                                                                                                                                                                                                                                                                                                                                                  1.0                                  0.1[\*](#tf2){ref-type="table-fn"}   0.1                                   0.1                                  0.1                                  0.1                                  0.1[\*](#tf2){ref-type="table-fn"}    0.0                                   0.1[\*](#tf2){ref-type="table-fn"}   0.1[\*](#tf2){ref-type="table-fn"}   0.0
  15                                                                                                                                                                                                                                                                                                                                                                                       1.0                                  0.1                                   0.0                                  0.1                                  0.0                                  0.1                                   0.0                                   0.1                                  0.1                                  0.2[\*](#tf2){ref-type="table-fn"}
  16                                                                                                                                                                                                                                                                                                                                                                                                                            1.0                                   0.1                                  0.0                                  0.2[\*](#tf2){ref-type="table-fn"}   0.1                                   0.1                                   0.0                                  0.0                                  0.1
  17                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1.0                                  0.1[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}   0.3[\*](#tf2){ref-type="table-fn"}    0.2[\*](#tf2){ref-type="table-fn"}    0.1[\*](#tf2){ref-type="table-fn"}   0.2[\*](#tf2){ref-type="table-fn"}   0.0
  18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.0                                  0.2[\*](#tf2){ref-type="table-fn"}   0.3[\*](#tf2){ref-type="table-fn"}    0.2[\*](#tf2){ref-type="table-fn"}    0.1                                  0.0                                  0.1
  19                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1.0                                  0.3[\*](#tf2){ref-type="table-fn"}    0.1[\*](#tf2){ref-type="table-fn"}    0.0                                  0.1[\*](#tf2){ref-type="table-fn"}   0.1
  20                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 1.0                                   0.2[\*](#tf2){ref-type="table-fn"}    0.1                                  0.1[\*](#tf2){ref-type="table-fn"}   0.0
  21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.0                                   0.1[\*](#tf2){ref-type="table-fn"}   0.1                                  0.1
  22                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             1.0                                  0.2[\*](#tf2){ref-type="table-fn"}   0.3[\*](#tf2){ref-type="table-fn"}
  23                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  1.0                                  0.2[\*](#tf2){ref-type="table-fn"}
  24                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1.0

*p* \< 0.05

###### Spearman pairwise correlations for CpG sites of *CDKN2B*.

  Position   1     2     3     4     5     6     7     8     9     10    11    12
  ---------- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----
  1          1.0   0.5   0.5   0.4   0.6   0.6   0.6   0.3   0.3   0.4   0.5   0.4
  2                1.0   0.5   0.5   0.5   0.5   0.5   0.3   0.3   0.4   0.3   0.3
  3                      1.0   0.4   0.5   0.5   0.5   0.3   0.3   0.3   0.3   0.3
  4                            1.0   0.5   0.5   0.5   0.3   0.3   0.3   0.4   0.4
  5                                  1.0   0.8   0.7   0.4   0.4   0.6   0.5   0.5
  6                                        1.0   0.8   0.4   0.4   0.6   0.5   0.6
  7                                              1.0   0.3   0.4   0.5   0.5   0.5
  8                                                    1.0   0.3   0.3   0.3   0.3
  9                                                          1.0   0.6   0.6   0.5
  10                                                               1.0   0.8   0.7
  11                                                                     1.0   0.7
  12                                                                           1.0

All *p* \< 0.001

###### Differences of methylation levels between patients with and without AAC.

  Gene       Position   AAC                 *P* value           
  ---------- ---------- ------------------- ------------------- --------------
  *CDKN2A*   1          4.20 (2.82--5.88)   4.33 (2.74--6.19)   0.571
             2          6.89 (5.30--8.90)   7.13 (5.51--8.55)   0.844
             3          8.09 (6.62--10.4)   8.02 (6.25--10.0)   0.379
             4          5.86 (4.25--7.81)   5.80 (4.38--7.87)   0.864
             5          4.80 (4.04--5.49)   5.08 (4.33--5.59)   0.132
             6          2.79 (2.34--3.36)   2.56 (2.09--3.07)   **0.038**
             7          2.33 (1.87--2.83)   2.27 (1.77--2.71)   0.174
             8          4.43 (3.78--5.08)   4.01 (3.56--4.67)   **0.037**
             9          4.30 (2.37--7.33)   5.26 (3.27--8.83)   0.130
             10         2.04 (0.96--3.23)   1.75 (1.00--2.56)   0.233
             11         3.57 (2.38--4.89)   3.70 (2.22--5.13)   0.885
             12         0.96 (0.57--1.34)   0.88 (0.56--1.25)   0.363
             13         1.20 (0.96--1.49)   1.34 (0.94--1.52)   0.441
             14         1.21 (1.03--1.46)   1.11 (0.88--1.41)   **0.039**
             15         2.05 (1.66--2.41)   1.93 (1.54--2.48)   0.630
             16         1.33 (1.02--1.66)   1.35 (1.08--1.62)   0.906
             17         3.23 (2.64--3.97)   3.01 (2.48--3.46)   **0.005**
             18         2.19 (1.71--2.61)   2.14 (1.74--2.53)   0.487
             19         2.49 (2.01--2.97)   2.48 (1.96--2.87)   0.827
             20         2.75 (2.18--3.27)   2.60 (2.10--3.07)   0.259
             21         15.5 (13.5--17.2)   15.6 (14.4--17.1)   0.313
             22         2.52 (2.08--3.15)   2.62 (2.07--3.20)   0.762
             23         4.27 (3.50--5.09)   4.32 (3.51--4.84)   0.853
             24         1.69 (1.26--2.46)   1.77 (1.31--2.48)   0.631
             Average    3.95 (3.58--4.27)   3.92 (3.67--4.23)   0.909
                                                                
  *CDKN2B*   1          5.43 (4.51--6.44)   4.97 (4.04--5.81)      **0.005**
             2          4.45 (3.48--5.34)   3.99 (3.06--5.06)      **0.014**
             3          3.89 (3.10--4.87)   3.86 (3.10--4.64)      0.700
             4          4.20 (3.53--5.11)   3.89 (3.14--4.41)      **0.007**
             5          7.66 (6.65--8.80)   6.65 (5.80--7.68)   **\< 0.001**
             6          6.95 (5.99--8.12)   6.00 (5.04--6.80)   **\< 0.001**
             7          8.12 (7.04--9.49)   7.10 (6.41--7.92)   **\< 0.001**
             8          3.52 (3.03--4.11)   3.07 (2.76--3.49)   **\< 0.001**
             9          3.94 (3.34--4.47)   3.41 (2.76--3.82)   **\< 0.001**
             10         6.08 (5.21--7.03)   5.11 (4.20--5.92)   **\< 0.001**
             11         7.53 (6.32--8.72)   6.56 (5.47--7.05)   **\< 0.001**
             12         5.74 (5.02--6.70)   5.01 (4.37--5.60)   **\< 0.001**
             Average    5.72 (5.03--6.34)   4.94 (4.48--5.47)   **\< 0.001**

As shown in **[Table 4](#T4){ref-type="table"}**, generalized liner model detected a positive correlation between average methylation levels of *CDKN2B* and log-transformed calcification scores (*β* = 0.275 ± 0.116, *P* = 0.018) after adjusting for age, sex, HTN, DM, dyslipidemia, and smoking. The association still remained after further correction for multiple comparison (corrected *P* = 0.036).

###### Association of methylation levels and log-transformed calcification scores detected by generalized liner model.

                     *β*      SE      *P* value
  ------------------ -------- ------- --------------
  Model 1                             
      *CDKN2A*       −0.011   0.220   0.961
      Age            0.159    0.011   **\< 0.001**
      Sex            −0.065   0.297   0.827
      HTN            0.600    0.299   **0.044**
      DM             0.039    0.257   0.880
      Dyslipidemia   −0.137   0.245   0.576
      Smoking        −0.016   0.272   0.954
  Model 2                             
      *CDKN2B*       0.275    0.116   **0.018**
      Age            0.148    0.012   **\< 0.001**
      Sex            −0.057   0.295   0.847
      HTN            0.653    0.296   **0.027**
      DM             0.042    0.253   0.869
      Dyslipidemia   −0.077   0.244   0.751
      Smoking        −0.049   0.269   0.854

Generalized liner model was adjusted for age, sex, HTN, DM, dyslipidemia and smoking.

Further, we assessed the association between rs4977574 and methylation of *CDKN2B*. After adjusting for potential risk factors, rs4977574 (G as coded allele) was associated with AAC in the study population (*β* = 0.414 ± 0.171, *P* = 0.015). There were no differences in average methylation levels of *CDKN2B* among three genotypes of rs4977574 (AA vs AG vs GG: 5.56 vs 5.58 vs 5.46, *P* = 0.626). When rs4977574 was further added into the generalized linear model, the average methylation levels of *CDKN2B* still correlated with log-transformed calcification scores (*β* = 0.292 ± 0.115, *P* = 0.011) (**[Table 5](#T5){ref-type="table"}**).

###### Association of *CDKN2B* methylation levels and AAC after adjustment of rs4977574 and other confounders.

  Variants       *β*      SE      *P* value
  -------------- -------- ------- --------------
  *CDKN2B*       0.292    0.115   **0.011**
  Age            0.148    0.012   **\< 0.001**
  Sex            0.01     0.293   0.972
  HTN            0.645    0.293   **0.028**
  DM             0.112    0.252   0.656
  Dyslipidemia   −0.072   0.242   0.766
  Smoking        −0.125   0.268   0.641
  Rs4977574      0.439    0.170   **0.010**

Discussion
==========

This study observed that methylation levels of *CDKN2B* were relatively higher in patients with AAC than those in patients without AAC. A positive correlation between *CDKN2B* methylation and AAC load was detected. These results verified our hypothesis that DNA methylation in *CDKN2B* may increase the susceptibility of artery calcification.

*CDKN2B* is a well-characterized tumor suppressor gene which is involved in cell cycle regulation via retinoblastoma (Rb) pathway^[@bib29])^. The p15^INK4b^ protein encoded by *CDKN2B* can specifically bind to CDKN4/6 and result in G1 phase arrest and cell proliferation interruption^[@bib12])^. Methylation in CpG islands around promoter regions can generally reduce gene expression^[@bib30])^. Evidence that *CDKN2B* methylation represses expression and leads to unlimited cell proliferation has been confirmed in a spectrum of cancers^[@bib21],\ [@bib31])^.

Both inflammatory responses and migration of proliferating vascular smooth muscle cells (VSMCs) are considered essential for the development of atherosclerosis^[@bib32])^. Chronic vascular inflammation arising from atherosclerosis also contributes to arterial calcification^[@bib10])^. Under certain circumstances, a subpopulation of VSMCs may be predisposed to differentiate into osteoblastic and proliferative phenotypes. They can acquire osteoblast-like characteristics and become calcifying vascular cells, participating in spontaneous mineral deposition^[@bib33]--[@bib35])^. As the expression of *CDKN2B* is repressed, Rb proteins may lose control and result in increased proliferation of macrophages and VSMCs^[@bib15],\ [@bib19])^.

The association of *CDKN2B* methylation and coronary artery disease (CAD) has been previously observed^[@bib20])^. Zhuang and colleagues found that the methylation levels of *CDKN2B* were significantly higher in CAD patients than in controls. Based on quantitative assessment of calcification, our study observed similar results in the aortic arch. Therefore, the higher the methylation level, the more serious the artery calcification might be.

Methylation levels of *CDKN2B* were not directly linked to genotypes of rs4977574, which was associated with AAC in previous and in our studies. It was possible that genetic variants directly contribute to *ANRIL* expression rather than to *CDKN2B* methylation according to evidence from previous studies^[@bib12],\ [@bib36])^. *CDKN2B* methylation was likely to be modulated by *ANRIL* or other epigenetic changes.

There are several limitations to our study. First, the nature of the cross-sectional study limited us to reach a causal inference. We cannot determine if the observed associations is attributed to methylation effects on AAC or vice versa. Second, *CDKN2A/2B* expression was not tested in this study due to lack of fresh leukocytes, which prevented us from evaluating the interactions between methylation variation and *CDKN2A/2B* gene expression. Therefore, future studies need to be conducted to provide more functional evidence. Third, considering varied predisposition of DNA methylation in different tissues, methylation measured from white blood cells may not represent that of vessel walls, although the role of white blood cells in atherogenesis is well-defined^[@bib32])^. Because of the difficulty in obtaining vascular tissues from human body via invasive therapy, methylation tests from peripheral blood is still a convenient and rational method for investigation. In addition, a larger sample size is favorable for confirmation and more reliable results. The study was conducted in subjects with ischemic stroke, which may lead to selection bias as the prevalence of AAC was higher than that in the general population. Therefore, further exploration in the population with health controls is more convincible.

In conclusion, *CDKN2B* methylation is independently associated with AAC. Patients with higher methylation levels in *CDKN2B* may have increased risk for AAC. Further studies on the underlying mechanisms of this association are warranted to establishing a cause--effect relationship.

This work was supported by the National Natural Science Foundation of China (NSFC, \# 81571143 to GX, \# 81530038 to XL and \# 81220108008 to XL). We thank all patients for participating in this study. We are also grateful to Center for Genetics & Genomic Analysis, Genesky Biotechnologies Inc. (Shanghai, 201203) for their technical support in sequencing.

Conflict of Interest
====================

None.
